Search
Nov 21, 2023
BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances
Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 in ADH1 and investing in early science.
Apr 27, 2023
BridgeBio's Neil Kumar on drug development
BridgeBio's Neil Kumar shares experiences that may be good learnings for other drug developers and discusses his company's unique model.